Tscan Therapeutics Short Interest Ratio and Short Volume

Tscan Therapeutics (NASDAQ:TCRX) Short Interest Frequently Asked Questions

What is Tscan Therapeutics' current short interest?

Short interest is the volume of Tscan Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 92,500 shares of TCRX short. 1.00% of Tscan Therapeutics' shares are currently sold short. Learn More on Tscan Therapeutics' current short interest.

What is a good short interest ratio for Tscan Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Tscan Therapeutics currently has a short interest ratio of 1.0. Learn More on a good short interest ratio for Tscan Therapeutics

What is a good short interest percentage for Tscan Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.00% of Tscan Therapeutics' floating shares are currently sold short.

Is Tscan Therapeutics' short interest increasing or decreasing?

Tscan Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 92,500 shares, an increase of 2,102.4% from the previous total of 4,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Tscan Therapeutics' float size?

Tscan Therapeutics currently has issued a total of 23,966,000 shares. Some of Tscan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Tscan Therapeutics currently has a public float of 9,290,000 shares.

How does Tscan Therapeutics' short interest compare to its competitors?

1.00% of Tscan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Tscan Therapeutics: Graphite Bio, Inc. (12.89%), Aligos Therapeutics, Inc. (7.41%), Curis, Inc. (12.00%), Talaris Therapeutics, Inc. (5.07%), Taysha Gene Therapies, Inc. (13.02%), Molecular Partners AG (0.00%), Tarsus Pharmaceuticals, Inc. (3.49%), Finch Therapeutics Group, Inc. (1.43%), Precision BioSciences, Inc. (4.89%), and Acumen Pharmaceuticals, Inc. (2.42%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($7.35 billion), Advanced Micro Devices, Inc. ($6.43 billion), Charter Communications, Inc. ($5.68 billion), Wayfair Inc. ($4.48 billion), Uber Technologies, Inc. ($3.77 billion), Canadian Pacific Railway Limited ($3.73 billion), Palo Alto Networks, Inc. ($3.10 billion), Zoom Video Communications, Inc. ($2.87 billion), Match Group, Inc. ($2.83 billion), and DoorDash, Inc. ($2.54 billion). View all of the most shorted stocks.

What does it mean to sell short Tscan Therapeutics stock?

Short selling TCRX is an investing strategy that aims to generate trading profit from Tscan Therapeutics as its price is falling. Tscan Therapeutics' stock is trading up $0.29 today. To short Tscan Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Tscan Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Tscan Therapeutics?

A short squeeze for Tscan Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TCRX, which in turn drives the price of the stock up even further.

How often is Tscan Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCRX, twice per month. The most recent reporting period available is September, 30 2021.